A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
Stopped early · Phase 3
Conditions studied: Epidermolysis Bullosa
In brief
The purpose of this study is to evaluate the efficacy and safety of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing. It is hypothesized that ABH001 may initiate and continue wound healing in patients with epidermolysis bullosa.
Key facts
- Study ID
- NCT01749306
- Run by
- Shire Regenerative Medicine, Inc.
- People needed
- 1
- Starts
- 2012-12-01
- Expected to finish
- 2013-11-01
- Last updated by the study team
- 2013-11-21
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The subject or legal guardian must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and must be able to and willing to follow study procedures and instructions
- Male and female subjects.
- Stable nutritional status.
- Subjects with a confirmed diagnosis of generalized Epidermolysis Bullosa (EB)
- Cutaneous wounds meeting the following criteria:
- Anatomical location: arms, legs, thorax, or back above the waistline and below the neck.
- Documented age (duration) of the wound(s).
- One or more wounds capable of potentially meeting the following wound selection criteria at the end of the observation period:
- i. Two clinically non-infected cutaneous wounds with no clinically meaningful change in wound size during the observation period.
- ii. Two matched wounds.
- Negative urine pregnancy test for women of child-bearing potential.
- Female subjects of childbearing potential and male subjects of procreative capacity must agree to use an effective method of contraception.
You may not qualify if…
- Pregnant or nursing women.
- Diagnosis of non-genetic generalized EB.
- Localized, active clinical infection of study wounds.
- Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures.
- Known allergy to bovine products.
- Known allergy to silver products.
- Systemic infection at the time of enrolment in the study.
- Currently receiving or have received oral steroid therapy within the previous 4 weeks.
- Taking, or have participated in other clinical studies involving gene therapy, stem cell therapy, recombinant DNA/protein therapy.
- Received ABH001, or other biologic or cell therapy for the treatment of EB in the study wound sites within the previous 3 months.
- Hypersensitivity to any of the therapeutic agents.
- History of malignant skin disease.
Where it is running
- Phoenix Children's Hospital — Phoenix, Arizona, United States
- Lucile Packard Children's Hospital at Stanford University — Redwood City, California, United States
- Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology — San Diego, California, United States
- Denver Children's Hospital — Aurora, Colorado, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
- Virginia Clinical Research, Inc — Norfolk, Virginia, United States
- Landeskrankenhaus Salzburg-Universitätsklinikum der Paracelsus Medizinischen Privatuniversität — Salzburg, State of Salzburg, Austria
- Toronto Regional Wound Healing Clinic — Mississauga, Ontario, Canada
- University of Montreal — Montreal, Quebec, Canada
- Hôpital Necker-Enfants Malades — Paris, Île-de-France Region, France
- University of Freiburg (Studiensekretariat Hautklinik Universitätsklinikum Freiburg - Hautklinik) — Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Warszawki Uniwersytet Medyczny Katedra I Klinika Dermatologiczna — Warsaw, Masovian Voivodeship, Poland
- Hospital CUF Descobertas — Lisbon, Lisbon District, Portugal
- Hospital Universitario La Paz — Madrid, Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.